Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis
- 52 Downloads
The continuous intake of antithrombotic drugs during holmium laser enucleation of the prostate (HoLEP) remains nonconsensual. We aim to pool those controversial evidence and provide practical guidance of oral antithrombotics on HoLEP for benign prostate hyperplasia (BPH).
PubMed, Embase and CENTRAL database were systematically searched up to June 2019 for trials on patients with and without oral antithrombotics undergoing HoLEP. Number of events and mean value with standard deviation were, respectively, extracted for dichotomous and continuous parameters. Subgroup analyses of anticoagulation and antiplatelet were also performed. All statistical analyses were conducted with Review Manager v.5.3 software. Newcastle–Ottawa Scale (NOS) was used to assess the quality of selected trials.
Nine studies with 5528 patients were eventually selected, and patients included were generally older than 65 years. It revealed that the non-antithrombotic group had a lower rate of blood transfusion (OR 0.21, 95% CI 0.10–0.45, P < 0.0001), bladder tamponade (OR 0.30, 95% CI 0.13–0.69, P = 0.004) and acute urine retention (OR 0.52, 95% CI 0.30–0.89, P = 0.02). Operation time was also shorter (MD − 10.31, 95% CI − 12.76 to − 7.85, P < 0.00001) in the non-antithrombotic group, but the heterogeneity was considerable (I2 = 75%). Subgroup analyses were generally consistent with the primary analysis except the non-anticoagulation and anticoagulation group having similar operation time (MD 6.66, 95% CI − 7.15 to 20.48, P = 0.34).
The current study confirmed that continuous intake of antithrombotic drugs could significantly increase the risk of bleeding and blood transfusion, bladder tamponade and acute urine retention.
KeywordsBenign prostate hyperplasia (BPH) Holmium laser enucleation of the prostate (HoLEP) Antithrombotic Perioperative safety
This research is supported by National Natural Science Foundation of China (Grant Nos. 81702536, 81370855, 81770756), Programs from Science and Technology Department of Sichuan Province (Grant Nos. 2018HH0153 and 2017HH0063) and National key research and development program of China (Grant Nos. SQ2017YFSF090096).
QW, JZA, LY: project designation, public funding; XNZ, XH, HX: literature search and screening; XNZ, LP, DHC: data collection; XNZ, LP, DHC: data analysis, manuscript writing/editing; All the authors read and approved the final version.
Compliance with the ethical standard
Conflict of interest
The authors declare that they have no conflict of interest.
Not applicable as there are no study participants.
Research involving human participants and/or animals
Not applicable as there are no human participants and/or animals.
- 2.Roehrborn CG (2005) Benign prostatic hyperplasia: an overview. Rev Urol 7(Suppl 9):S3–s14Google Scholar
- 3.Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109. https://doi.org/10.1016/j.eururo.2014.12.038 CrossRefGoogle Scholar
- 4.EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2Google Scholar
- 8.Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R, Cestari A, Briganti A, Mazzoccoli B, Rigatti P, Montorsi F (2006) Holmium laser enucleation of the prostate versus open prostatectomy for prostates > 70 g: 24-month follow-up. Eur Urol 50(3):563–568. https://doi.org/10.1016/j.eururo.2006.04.003 CrossRefGoogle Scholar
- 9.Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67(6):1066–1096. https://doi.org/10.1016/j.eururo.2014.06.017 CrossRefGoogle Scholar
- 11.Kuntz RM, Ahyai S, Lehrich K, Fayad A (2004) Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol 172(3):1012–1016. https://doi.org/10.1097/01.ju.0000136218.11998.9e CrossRefGoogle Scholar
- 12.Kosmidou I, Liu Y, Alu MC, Liu M, Madhavan M, Chakravarty T, Makkar R, Thourani VH, Biviano A, Kodali S, Leon MB (2019) Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv 12(16):1580–1589. https://doi.org/10.1016/j.jcin.2019.06.001 CrossRefGoogle Scholar
- 14.Golabek T, Powroznik J, Szostek P, Chlosta P, Borowka A (2013) Percutaneous suprapubic endoscopy for treatment of bladder tamponade. Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other mini-invasive techniques 8 (4):364–365. https://doi.org/10.5114/wiitm.2011.35637Google Scholar
- 16.Boeri L, Capogrosso P, Ventimiglia E, Fontana M, Sampogna G, Zanetti SP, Pozzi E, Zuabi R, Schifano N, Chierigo F, Longo F, Gadda F, Dell’Orto PG, Scattoni V, Montorsi F, Montanari E, Salonia A (2019) Clinical comparison of holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate in patients under either anticoagulation or antiplatelet therapy. Eur Urol Focus. https://doi.org/10.1016/j.euf.2019.03.002 Google Scholar
- 23.Neuville P, Codas R, Ravier E, Maucort-Boulch D, Badet L, Fassi-Fehri H (2018) Anticoagulation impact on bleeding risk during HoLEP: monocentric study of 156 patients. Progres en urologie: journal de l’Association francaise d’urologie et de la Societe francaise d’urologie 28(2):128–134. https://doi.org/10.1016/j.purol.2017.10.013 CrossRefGoogle Scholar
- 25.Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216. https://doi.org/10.1007/s00345-010-0561-3 CrossRefGoogle Scholar
- 27.Zheng X, Qiu Y, Qiu S, Tang L, Nong K, Han X, Li M, Quan L, Yang L, Wei Q (2019) Photoselective vaporization has comparative efficacy and safety among high-risk benign prostate hyperplasia patients on or off systematic anticoagulation: a meta-analysis. World J Urol 37(7):1377–1387. https://doi.org/10.1007/s00345-018-2530-1 CrossRefGoogle Scholar
- 28.Michielsen DP, Coomans D, Van Lersberghe C, Braeckman JG (2011) Comparison of the haemostatic properties of conventional monopolar and bipolar transurethral resection of the prostate in patients on oral anticoagulants. World J Urol 7(5):858–863. https://doi.org/10.5114/aoms.2011.25562 Google Scholar
- 29.Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140. https://doi.org/10.1016/j.eururo.2013.03.004 CrossRefGoogle Scholar